<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
    <meta content="width=device-width, initial-scale=1.0" name="viewport">
    <title>GA TB Reference Guide </title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">
</head>


<body>
<div class="uk-container">
    <div class="chapter-header"> 
        <div class="header-title">
            <div>
                <img src="ic_chart.svg" width="16" height="16" class="ic_chapter_icon">
            </div>
            <p class="chapter-title">18. Dosage Adjustments for ART and Rifamycins when used in Combination</p>
        </div>
        <p> <span class="view-in-chapter-highlight"> View in chapter → <span> <a href="5_treatment_of_current_(active)_disease_therapy__f__tb_and_hiv.html#table18"> Antiretroviral Therapy (ART) and Treatment of Persons Living with HIV and Active TB </a></p>
        <p class="last-updated"><i>Last Updated October 2025</i></p>
    </div>
    <hr>
    <div class="uk-overflow-auto">
        <div class="uk-tabs-container">
            <div class="tabs">
            <button class="tab-button" onclick="switchTab(0, event)">Integrase<br>Inhibitor</button>
            <button class="tab-button" onclick="switchTab(1, event)">Boosted PI</button>
            <button class="tab-button" onclick="switchTab(2, event)">NNRTI</button>
        </div>

        <div class="tab-content">
            <p>Dolutegravir (DTG)</p>
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                    
                <tr>
                        <th>Drug</th>
                        <th>Dosing</th>
                    </tr>
                <tr>
                    <th class="uk-text-nowrap">Rifampin (RIF)</th>
                    <td>RIF: No change (600 mg)<br>DTG: Increase to 50 mg BID</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Rifabutin (RBT)</th>
                    <td>RBT: No change (300 mg)<br>DTG: No change (50 mg)</td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <p>ATV/r, DRV/r </p>
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
             <tr>
                        <th>Drug</th>
                        <th>Dosing</th>
                    </tr>
                <tr>
                    <th class="uk-text-nowrap">Rifampin (RIF)</th>
                    <td>DO NOT USE</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Rifabutin (RBT)</th>
                    <td>RBT: decrease to 150 mg/d<br>PIs: no change</td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <p>Efavirenz (EFV) <br> (Note: No longer a first line ART)</p>
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
          <tr>
                        <th>Drug</th>
                        <th>Dosing</th>
                    </tr>
                <tr>
                    <th class="uk-text-nowrap">Rifampin (RIF)</th>
                    <td>RIF no change (600 mg)<br>EFV: no change (600 mg qhs)</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Rifabutin (RBT)</th>
                    <td>DO NOT USE</td>
                </tr>
                </tbody>
            </table>
        </div>
         <p>
            Department of Human Health Services links for ART drug-drug interactions – these are updated frequently</p>
        <p>Protease inhibitors: <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-protease-inhibitors?view=full">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-protease-inhibitors?view=full</a></p>

        <p>NNRTIs: <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-nnrti?view=full">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-nnrti?view=full</a></p>

        <p>NRTIs: <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-nrti?view=full">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-nrti?view=full</a></p>

        <p>Integrase inhibitors: <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-insti?view=full">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-insti?view=full</a></p>
      
        <p>*Preliminary data suggest that there is an increased risk of neural tube defects in infants born to women
            who were receiving DTG at the time of conception. DTG is contraindicated for pregnant women during first
            trimester and for women who are planning to become pregnant or are not using effective contraception.
            DTG is the preferred integrase inhibitor after first trimester.</p>

        <ul>
            <li>NNRTIs: non-nucleoside reverse transcriptase inhibitors</li>
            <li>PIs: protease inhibitors</li>
            <li>ATV/r: Atazanavir/ritonavir</li>
            <li>DRV/r: Daraunavir/ritonavir</li>
            <li>LPV/r: Lopinavir/ritonavir</li>
            <li>RAL: Raltegravir</li>
            <li>DTG: Dolutegravir</li>
            <li>/c : boosted with cobicistat</li>
        </ul>

        <p>Table 18 is based on guidelines developed by the Department of Health and Human Services (DHHS) Panel on
            Guidelines for Use of Antiretroviral Agents for Adults and Adolescents and Use of Antiretroviral Drugs
            in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal Transmission in the United
            States, last reviewed and updated April 15, 2019
            <a href="http://aidsinfo.nih.gov/guidelines">(aidsinfo.nih.gov/guidelines)</a></p>

        <p>1-Data on integrase inhibitors and pregnancy outcomes is rapidly evolving and DHHS
            guidelines are frequently updated.</p>

        <p>2-Cobicistat is currently not recommended for pregnant women.</p>
        </div>
    </div>
</div>
</body>

<script src="../assets/uikit.js" type="text/javascript"></script>
<script src="../assets/uikit-icons.js" type="text/javascript"></script>
<script src="main.js" type="text/javascript"></script>
<script>
    // Initialize the first tab as active
    document.addEventListener('DOMContentLoaded', function() {
        const tableContainer = document.querySelector('.uk-tabs-container');
        const firstTab = tableContainer.querySelector('.tab-button');
        firstTab.classList.add('active-option');
        const firstContent = tableContainer.querySelector('.tab-content');
        firstContent.classList.add('active-tab');
        firstContent.classList.add('active-option');
    });
</script>
</html>
